Literature DB >> 12450607

Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty.

Cheol Whan Lee1, Dae-Hyuk Moon, Myeong-K i Hong, Jae-Hwan Lee, S i-Wan Choi, Hyun Suk Yang, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450607     DOI: 10.1016/s0002-9149(02)02843-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  5 in total

Review 1.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Comparison of myocardial contrast echocardiography versus rest sestamibi myocardial perfusion imaging in the early diagnosis of acute coronary syndrome.

Authors:  Soo-Jin Kang; Duk-Hyun Kang; Jong-Min Song; Jae-Kwan Song; Seong-Wook Park; Seung-Jung Park
Journal:  J Cardiovasc Ultrasound       Date:  2010-06-30

3.  Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice.

Authors:  T Heer; U Zeymer; C Juenger; A K Gitt; H Wienbergen; R Zahn; M Gottwik; J Senges
Journal:  Heart       Date:  2006-04-10       Impact factor: 5.994

Review 4.  Antithrombotic therapies in primary angioplasty: rationale, results and future directions.

Authors:  Giuseppe De Luca; Paolo Marino
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

Authors:  Giuseppe De Luca; Eliano Navarese; Paolo Marino
Journal:  Eur Heart J       Date:  2009-10-28       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.